Clinical trials: Magnetic Resonance Angiography
Arterial Occlusive Disease
A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography
This is a clinical study of gadoteric acid in non-coronary MR angiography.
- Trial name
- NCT00447889
- Testing
- gadoteric acid
- Where
- South Korea
- Sponsor
- Guerbet
Type 2 Diabetes Mellitus, Coronary Atherosclerosis
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitus and to assess its…
- Trial name
- ACCREDIT (NCT01254552)
- Testing
- iobitridol, gadoterate meglumine
- Where
- South Korea
- Volunteers
- 351 people
- Sponsor
- Guerbet
Polyarticular Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
This is an open-label, extension, Phase III study to evaluate the long-term safety, efficacy and PK of MRA in patients with pJIA who participated in Study MRA318JP.
- Trial name
- NCT00144625
- Testing
- MRA(Tocilizumab)
- Volunteers
- 19 people
- Sponsor
- Chugai Pharmaceutical
Diagnostic Imaging
Magnevist Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Magnevist at a dose of more than 0.2 ml/kg for MR angiography of peripheral…
- Trial name
- NCT01376739
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- Japan
- Volunteers
- 2,051 people
- Sponsor
- Bayer
Carotid, Aortic, Renal or Peripheral Artery Disease
Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries
To compare two gadolinium contrast agents in terms of global paired diagnostic preference (primary endpoint) for the assessment of contrast-enhanced MR Angiography of the carotid, renal/abdominal and peripheral arteries
- Trial name
- VALUE (NCT01260636)
- Testing
- Gadobenate Dimeglumine, Gadopentetate Dimeglumine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bracco Diagnostics, Inc
Steno-occlusive Disease
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market.
- Trial name
- NCT00415805
- Testing
- Multihance, vasovist
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Bracco Diagnostics, Inc
Rheumatoid Arthritis
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment
- Trial name
- NCT00661284
- Where
- 5 sites in Japan
- Volunteers
- 189 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.
- Trial name
- NCT00144547
- Testing
- MRA(Tocilizumab)
- Volunteers
- 241 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA213JP.
- Trial name
- NCT00144534
- Testing
- MRA (Tocilizumab)
- Volunteers
- 115 people
- Sponsor
- Chugai Pharmaceutical
Magnetic Resonance Imaging
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has already been approved for application in adults, will be investigated in children and adolescents.
- Trial name
- NCT00468819
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- Bayer
Renal Artery Obstruction
Gadobutrol Enhanced MRA of the Renal Arteries
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GRAMS (NCT01344460)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in United States, Argentina and 11 more
- Volunteers
- 317 people
- Sponsor
- Bayer
Renal Artery Stenosis
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.
- Trial name
- NCT00209391
- Testing
- Gadodiamide Injection
- Where
- Germany
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
Peripheral Arterial Disease (PAD)
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries.
- Trial name
- NCT00707876
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Peripheral Arterial Disease
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- NCT00955617
- Testing
- Contrast-enhanced MRA - Imaging examination
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Guerbet
Magnetic Resonance Imaging, Magnetic Resonance Angiography
GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients
Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with Gadovist®.
- Trial name
- GARDIAN (NCT01095081)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 20 sites in Bosnia and Herzegovina, Canada and 18 more
- Volunteers
- 23,775 people
- Sponsor
- Bayer
Rheumatoid Arthritis
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
This is an open-label, clinical pharmacology study to evaluate the safety and PK of MRA in patients with RA with Renal Impairment.
- Trial name
- NCT00144573
- Testing
- MRA(Tocilizumab)
- Volunteers
- 14 people
- Sponsor
- Chugai Pharmaceutical
Steno-occlusive Disease
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI
- Trial name
- NCT07348640
- Testing
- gadopiclenol, Gadoterate meglumine (Dotarem)
- Where
- 43 sites in United States, Canada and 8 more
- Volunteers
- 315 people
- Sponsor
- Guerbet
Peripheral Vascular Disease
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the infrarenal aorta and peripheral arteries.
- Trial name
- NCT00185276
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Volunteers
- 365 people
- Sponsor
- Bayer
Magnetic Resonance Angiography, Peripheral Vascular Diseases
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdominal, femoral, and leg…
- Conditions
- Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases
- Trial name
- NCT00652418
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01012674
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Guerbet